Business Wire

Theorem, LLC Launches Theorem Orbital, a New Division Providing an End-to-End Suite of Space and Satellite Logistics Services

4.8.2021 13:00:00 EEST | Business Wire | Press release

Share

Theorem, LLC, an innovation and engineering firm that builds custom enterprise software for the world’s most admired brands, today launched Theorem Orbital, a new division focused on end-to-end space logistics and enablement for the Global 2000.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210804005393/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

“We see space as a major driver of disruption,” Brim-DeForest says. “But in order for our clients to compete, they need help navigating it.” (Graphic: Business Wire)

“Today, only 100 of the Global 2000 have active space programs, but that number will increase tenfold over the next decade,” said Brady Brim-DeForest, CEO of Theorem. “The space industry can seem intimidating and hard to navigate — we are here to help make navigating it easy and transparent.”

While recent space-related startups have focused primarily on delivering launch-side capability, other aspects of the space industry are experiencing significant growth, and game-changing opportunities have become within reach for even those who have made minimal investments to date. These include bespoke satellite programs focused on activities like earth observation, remote sensing, and satellite-enabled communications and connectivity.

Theorem Orbital will leverage its direct relationships with space launch providers, prime contractors and suppliers, universities, and NGOs, allowing for a wide range of services tailored to clients expanding their existing footprint, or building a space strategy from the ground up. Theorem Orbital’s preferred providers for launch services and space-based data today include Rocket Lab, Virgin Orbit, Firefly Aerospace, and Satellogic.

“Our partnership with Theorem will help further our mission of democratizing access to Earth Observation data,” said Thomas VanMatre, Satellogic’s Vice President of Global Business Development. “The combination of Theorem’s world-class software innovation and engineering capabilities and Satellogic’s unit cost advantage will unlock a multitude of use cases for the commercial market.”

As part of its commitment to opening up access to space as a strategic resource for the enterprise, mid-market, and academic markets, Theorem is also announcing a strategic investment into bluShift Aerospace, the Brunswick, Maine based maker of the Starless Rogue launch platform that is designed to enable a low barrier to entry for a diverse collection of payloads into the suborbital space ecosystem.

"bluShift’s approach to developing cost-effective and sustainable next-generation rocket technology will open up space to new markets," said Sascha Deri, CEO of bluShift Aerospace. "We feel that our mission and philosophy are well aligned with Theorem Orbital's commitment to lowering the barrier to entry for companies beginning to leverage space-based infrastructure in their mid and long-term strategic plans. We're pleased to welcome them as an investor, and excited to collaborate on uncovering opportunities to accelerate the adoption of bluShift capabilities within the enterprise market."

At launch, Theorem Orbital’s initial suite of services will include:

  • Satellite Data & Connectivity Strategy and Planning - Strategy services designed to enable clients to leverage data and connectivity generated by existing satellite infrastructure, as well as planning for proprietary constellations.
  • Advanced-Data Analysis - Real-time satellite imagery and remote communication networks are shifting how construction, agriculture, real estate, retail, travel, and mining industries run their daily operations, quarterly planning, risk management, insurance negotiations, and other major drivers of their bottom line. Data providers like Satellogic are opening new use cases daily — Theorem Orbital can help clients make the most of this rapidly evolving field.
  • Software Platform Development - Theorem Orbital designs and builds advanced proprietary software platforms that bring together advanced space-based data sources with existing internal enterprise data and systems.
  • Hardware Development - Theorem Orbital can assist clients in utilizing Satellogic’s unique hosted payload program to rapidly prototype and fly proprietary and commercial off-the-shelf sensors to meet client requirements.
  • Internet-in-Space - Theorem Orbital can assist clients in establishing their own IoT communications network in space including the design and launch of bespoke constellations through preferred launch providers.
  • Launch - Theorem Orbital partners with preferred providers — including Virgin Orbit, Rocket Lab, SpaceX, and more — in order to enable the launch of custom payloads into low-earth and near-earth orbit.

“The cost of putting satellites into space has been dramatically reduced due to the innovations from launch providers such as SpaceX, Rocket Lab, and others,” said Nicolas Spurlock, Director of Corporate Strategy at Theorem. “Now is the time for large enterprises to invest in building their own space-based infrastructure and gain an advantage in the new Space 2.0 era.”

Start charting your course to space by learning more at theoremorbital.com.

About Theorem

Theorem, LLC is an innovation and engineering firm that builds custom software for companies making bold bets to stay ahead. Through research, lean design, and agile delivery, we make great user experiences accessible to the enterprise. Founded in 2007, Theorem’s global cross-functional product development teams drive technology, process, and cultural transformation. To learn more about how we enable ambitious leaders to build better software, visit www.theorem.co or follow @TheoremCo.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Andrew Upah
Theorem, LLC Public Relations
press@theorem.co

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye